Richard Scott Struthers - Feb 20, 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Feb 20, 2025
Transactions value $
$0
Form type
4
Date filed
2/24/2025, 04:30 PM
Previous filing
Dec 4, 2024

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (Right to Buy) Award $0 +313K $0.00 313K Feb 20, 2025 Common Stock 313K $36.86 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2026.
F2 The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 20, 2025.